Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Lindau, A; Härdtner, C; Hergeth, SP; Blanz, KD; Dufner, B; Hoppe, N; Anto-Michel, N; Kornemann, J; Zou, J; Gerhardt, LM; Heidt, T; Willecke, F; Geis, S; Stachon, P; Wolf, D; Libby, P; Swirski, FK; Robbins, CS; McPheat, W; Hawley, S; Braddock, M; Gilsbach, R; Hein, L; von zur Mühlen, C; Bode, C; Zirlik, A; Hilgendorf, I.
Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression.
Basic Res Cardiol. 2016; 111(2):20-20
Doi: 10.1007/s00395-016-0535-8
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Zirlik Andreas
- Co-Autor*innen der Med Uni Graz
- Anto Michel Nathaly
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Macrophages in the arterial intima sustain chronic inflammation during atherogenesis. Under hypercholesterolemic conditions murine Ly6C(high) monocytes surge in the blood and spleen, infiltrate nascent atherosclerotic plaques, and differentiate into macrophages that proliferate locally as disease progresses. Spleen tyrosine kinase (SYK) may participate in downstream signaling of various receptors that mediate these processes. We tested the effect of the SYK inhibitor fostamatinib on hypercholesterolemia-associated myelopoiesis and plaque formation in Apoe(-/-) mice during early and established atherosclerosis. Mice consuming a high cholesterol diet supplemented with fostamatinib for 8 weeks developed less atherosclerosis. Histologic and flow cytometric analysis of aortic tissue showed that fostamatinib reduced the content of Ly6C(high) monocytes and macrophages. SYK inhibition limited Ly6C(high) monocytosis through interference with GM-CSF/IL-3 stimulated myelopoiesis, attenuated cell adhesion to the intimal surface, and blocked M-CSF stimulated monocyte to macrophage differentiation. In Apoe(-/-) mice with established atherosclerosis, however, fostamatinib treatment did not limit macrophage accumulation or lesion progression despite a significant reduction in blood monocyte counts, as lesional macrophages continued to proliferate. Thus, inhibition of hypercholesterolemia-associated monocytosis, monocyte infiltration, and differentiation by SYK antagonism attenuates early atherogenesis but not established disease when local macrophage proliferation dominates lesion progression.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Atherosclerosis - drug therapy
- Atherosclerosis - immunology
- Atherosclerosis - prevention & control
- Cell Adhesion - drug effects
- Cells, Cultured -
- Disease Progression -
- Drug Evaluation, Preclinical -
- Female -
- Intracellular Signaling Peptides and Proteins - antagonists & inhibitors
- Macrophages - drug effects
- Mice -
- Monocytes - drug effects
- Myelopoiesis - drug effects
- Oxazines - pharmacology
- Oxazines - therapeutic use
- Protein-Tyrosine Kinases - antagonists & inhibitors
- Pyridines - pharmacology
- Pyridines - therapeutic use
- Random Allocation -
- Syk Kinase -
- Find related publications in this database (Keywords)
- Atherosclerosis
- SYK
- Monocytes
- Macrophages
- Progenitors
- Proliferation
- Egress